9planetswebs

Tech Mahindra gets a 100% share in Orchid Cybertech for $3.27 million

Tech Mahindra gets a 100% share in Orchid Cybertech for $3.27 million

Tech Mahindra, the IT services and consulting firm, announced on Tuesday, February 20, that it has finalized the acquisition of a 100% stake in Orchid Cybertech Services (OCSI) via its wholly-owned subsidiary for a total of $3.27 million. In a regulatory filing, Tech Mahindra announced that its wholly-owned subsidiary, Customer Philippines Inc., has approved the…

Read More
Hyundai Motor India IPO: Could boost Maruti Suzuki India shares

Hyundai Motor India IPO: Could boost Maruti Suzuki India shares

Hyundai Motor India IPO: Emkay Global suggests that Maruti Suzuki might trade at comparable valuations to Hyundai. This is due to Suzuki’s heavy reliance on India and its alliance with Toyota, balanced by Hyundai’s strong global presence and premium brand positioning. With Hyundai’s Indian subsidiary, Hyundai Motor India, making strides as the second-largest passenger vehicle…

Read More
HDFC Bank shares: During the January selloff, these 5 MF houses purchased equities valued at Rs 11,400 crore.

HDFC Bank shares: During the January selloff, these 5 MF houses purchased equities valued at Rs 11,400 crore

HDFC Bank shares: During the January selloff, these 5 MF houses purchased equities valued at Rs 11,400 crore. HDFC Bank shares: Data compiled by PRIME Database indicates that ICICI Prudential Mutual Fund’s holding in the private bank surged to Rs 19,990.25 crore in January from Rs 19,074.69 crore in December. In January, five leading mutual…

Read More
Dr. Reddy's vying for Novartis' India arm stake?

Dr. Reddy’s vying for Novartis’ India arm stake?

Dr. Reddy’s vying for Novartis’ India arm stake? Dr.Reddy’s: The report emerged the day after Novartis AG declared a strategic review of its Indian subsidiary. This review, as stated by the firm, encompasses an evaluation of Novartis AG’s 70.68 percent shareholding in the company. Indian pharmaceutical giant Reportedly, Dr. Reddy is vying to acquire Novartis…

Read More